Literature DB >> 15695604

Reduced bone density in children on long-term warfarin.

Chris Barnes1, Fiona Newall, Vera Ignjatovic, Patricia Wong, Fergus Cameron, Graeme Jones, Paul Monagle.   

Abstract

Vitamin K is essential for development of normal bone density and achieving adequate peak bone mass in childhood and is thought to be important in preventing the development of osteoporosis in later life. Warfarin, a vitamin K antagonist, is being used with greater frequency in children. The long-term effect of warfarin on bone density of children is not known. We performed a case control study survey of bone density in children on long-term warfarin (n=17, average duration of warfarin treatment 8.2 y) compared with randomly selected controls (n=321). There was a marked reduction in bone mineral apparent density of lumbar spine between patients and controls [patients 0.10 g/cm3; 95% confidence interval (CI), 0.93-0.11 g/cm3, controls 0.12 g/cm3; 95% CI, 0.11-0.12 g/cm3, p<0.001). The lumbar spine areal bone mineral density Z-score of patients was reduced compared with controls [patients, -1.96 (95% CI, -2.52 to -1.40). This difference persisted after adjustment for age and body size. The etiology for the reduced bone density is likely to be multifactorial, however, screening of children on long-term warfarin for reduced bone density should be considered.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15695604     DOI: 10.1203/01.PDR.0000155943.07244.04

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  14 in total

Review 1.  The bone-vascular axis in chronic kidney disease.

Authors:  Linda Demer; Yin Tintut
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-07       Impact factor: 2.894

2.  Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Paul Monagle; Anthony K C Chan; Neil A Goldenberg; Rebecca N Ichord; Janna M Journeycake; Ulrike Nowak-Göttl; Sara K Vesely
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 3.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 4.  Current and future management of pediatric venous thromboembolism.

Authors:  Bryce A Kerlin
Journal:  Am J Hematol       Date:  2012-02-24       Impact factor: 10.047

5.  Long-term anticoagulation in Kawasaki disease: Initial use of low molecular weight heparin is a viable option for patients with severe coronary artery abnormalities.

Authors:  Cedric Manlhiot; Leonardo R Brandão; Zeeshanefatema Somji; Amy L Chesney; Catherine MacDonald; Rebecca C Gurofsky; Tarun Sabharwal; Nita Chahal; Brian W McCrindle
Journal:  Pediatr Cardiol       Date:  2010-04-30       Impact factor: 1.655

6.  Craniocervical arterial dissection in children: diagnosis and treatment.

Authors:  Nicholas V Stence; Laura Z Fenton; Neil A Goldenberg; Jennifer Armstrong-Wells; Timothy J Bernard
Journal:  Curr Treat Options Neurol       Date:  2011-12       Impact factor: 3.598

7.  Bone density in children with single ventricle physiology.

Authors:  Edgard A Bendaly; Linda A DiMeglio; William F Fadel; Roger A Hurwitz
Journal:  Pediatr Cardiol       Date:  2014-12-16       Impact factor: 1.655

8.  Timing of low bone mineral density and predictors of bone mineral density trajectory in children on long-term warfarin: a longitudinal study.

Authors:  M L Avila; E Pullenayegum; S Williams; A Shammas; J Stimec; E Sochett; K Marr; L R Brandão
Journal:  Osteoporos Int       Date:  2015-11-16       Impact factor: 4.507

9.  Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women.

Authors:  M H J Knapen; L J Schurgers; C Vermeer
Journal:  Osteoporos Int       Date:  2007-02-08       Impact factor: 4.507

10.  A multi-national trial of a direct oral anticoagulant in children with cardiac disease: Design and rationale of the Safety of ApiXaban On Pediatric Heart disease On the preventioN of Embolism (SAXOPHONE) study.

Authors:  R Mark Payne; Kristin M Burns; Andrew C Glatz; Danshi Li; Xiaodong Li; Paul Monagle; Jane W Newburger; Elizabeth A Swan; Olivia Wheaton; Christoph Male
Journal:  Am Heart J       Date:  2019-08-09       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.